These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 33188876)

  • 1. Designing precision medicine panels for drug refractory cancers targeting cancer stemness traits.
    Warrier S; Patil M; Bhansali S; Varier L; Sethi G
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188475. PubMed ID: 33188876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
    Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
    Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer stem cells (CSCs) in cancer progression and therapy.
    Najafi M; Farhood B; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer stem cell (CSC) resistance drivers.
    Najafi M; Mortezaee K; Majidpoor J
    Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
    Walcher L; Kistenmacher AK; Suo H; Kitte R; Dluczek S; Strauß A; Blaudszun AR; Yevsa T; Fricke S; Kossatz-Boehlert U
    Front Immunol; 2020; 11():1280. PubMed ID: 32849491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.
    Dzobo K; Senthebane DA; Ganz C; Thomford NE; Wonkam A; Dandara C
    Cells; 2020 Aug; 9(8):. PubMed ID: 32823711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
    Yan Y; Zuo X; Wei D
    Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis.
    Iqbal W; Alkarim S; AlHejin A; Mukhtar H; Saini KS
    Oncotarget; 2016 Nov; 7(46):76337-76353. PubMed ID: 27486983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells.
    Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
    Adv Cancer Res; 2016; 131():159-91. PubMed ID: 27451127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects.
    Yadav AK; Desai NS
    Stem Cell Rev Rep; 2019 Jun; 15(3):331-355. PubMed ID: 30993589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antrodia cinnamomea sensitizes radio-/chemo-therapy of cancer stem-like cells by modulating microRNA expression.
    Su YK; Shih PH; Lee WH; Bamodu OA; Wu ATH; Huang CC; Tzeng YM; Hsiao M; Yeh CT; Lin CM
    J Ethnopharmacol; 2017 Jul; 207():47-56. PubMed ID: 28602756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging.
    Shigdar S; Lin J; Li Y; Yang CJ; Wei M; Zhus Y; Liu H; Duan W
    Ther Deliv; 2012 Feb; 3(2):227-44. PubMed ID: 22834199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.
    Clara JA; Monge C; Yang Y; Takebe N
    Nat Rev Clin Oncol; 2020 Apr; 17(4):204-232. PubMed ID: 31792354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX2 in cancer stemness: tumor malignancy and therapeutic potentials.
    Mamun MA; Mannoor K; Cao J; Qadri F; Song X
    J Mol Cell Biol; 2020 Feb; 12(2):85-98. PubMed ID: 30517668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
    Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
    Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bad seed: Cancer stem cells in tumor development and resistance.
    Koren E; Fuchs Y
    Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
    Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer cells stemness: A doorstep to targeted therapy.
    Prasad S; Ramachandran S; Gupta N; Kaushik I; Srivastava SK
    Biochim Biophys Acta Mol Basis Dis; 2020 Apr; 1866(4):165424. PubMed ID: 30818002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.
    Zeng Z; Fu M; Hu Y; Wei Y; Wei X; Luo M
    Mol Cancer; 2023 Oct; 22(1):172. PubMed ID: 37853437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.